Celldex Therapeutics (CLDX) 3rd Annual Guggenheim Healthcare Innovation Conference summary
Event summary combining transcript, slides, and related documents.
3rd Annual Guggenheim Healthcare Innovation Conference summary
9 Nov, 2026Barzolvolimab phase III results
Phase III CSU results showed complete response in a majority of patients, prospective angioedema clearing at 12 weeks, and similar responses in omalizumab-refractory patients.
One regimen requires seven dosing days per year; HCPs highlighted rapid, durable responses that deepen over time, severe disease with angioedema, and biologic-refractory patients as key differentiators.
Phase II follow-up showed 41% of patients remained in complete response seven months after their last dose; phase III off-therapy durability data will follow treatment through 52 weeks and subsequent follow-up.
The overall safety profile was described as favorable; common KIT-mediated adverse events were mostly mild to moderate and expected to reverse, while serious and grade 3/4 event rates matched placebo.
Two phase III cases were adjudicated as probable anaphylaxis, both after the first barzolvolimab dose; a separate adjudicated anaphylaxis case occurred on placebo.
Regulatory and data milestones
BLA submission is guided for 2027, using the full 52-week data; the goal is to bring the therapy to patients as quickly as possible.
At AAAAI in February 2027, the planned presentation will cover 24-week efficacy, including primary and key secondary endpoints, 12- and 24-week results, and time course.
Additional presentations on secondary and exploratory endpoints are planned in the coming months; phase III off-therapy follow-up will come after the 52-week treatment period.
CIndU phase III trials are enrolling; further guidance is expected in the next few months. Atopic dermatitis data are expected by year-end, from a moderately severe population that allows prior therapies, including biologics.
Market and commercialization
In the U.S., an estimated 30% of CSU prevalence is diagnosed, and fewer than 20% of diagnosed patients clinically eligible for advanced therapy receive one.
Barzolvolimab is positioned for first-line patients with severe disease or angioedema, estimated at at least 25% of first-line patients, and as a second-line option for patients with ongoing symptoms.
Other therapies have complete response rates of 30%–38%; one-year real-world attrition for patients starting omalizumab or dupilumab is 50%, supporting a substantial second-line opportunity.
Preliminary payer discussions support a premium, value-based pricing strategy; commercial preparations include expanding the MSL team and building market analytics, brand, and payer teams.
Payer exchange under PIE is anticipated in H1 2027; infrastructure development is described as disciplined, data-based, milestone-driven, and focused on high-value prescriber accounts.
Latest events from Celldex Therapeutics
- Phase 3 CSU success supports a 2027 BLA, backed by $650.3M in liquidity.CLDX
Q3 2026 - Barzolvolimab achieved rapid, durable efficacy and safety in severe, refractory CSU, meeting all endpoints.CLDX
Study result - Barzolvolimab's phase III data and commercial plans highlight innovation in advanced urticaria therapy.CLDX
12th Annual Cantor Fitzgerald Global Healthcare Conference - Barzolvolimab delivers rapid, durable efficacy in CSU, with major data milestones expected in 2026.CLDX
Corporate presentation - Q2 2026 net loss rose 30% as R&D spending surged, but liquidity remains strong through 2028.CLDX
Q2 2026 - No efficacy seen in prurigo nodularis; program discontinued, safety profile remains favorable.CLDX
Study result - Phase 2 and 52-week data in CSU and CIndU drive phase 3 launches and broad clinical expansion.CLDX
Guggenheim Securities Inaugural Healthcare Innovation Conference - All proposals passed, with strong financials and pipeline progress highlighted.CLDX
AGM 2026 - Barzolvolimab showed rapid, significant disease control in CIndU and is advancing to Phase 3.CLDX
Status Update